Liquid Biopsy Collection Study

N/AActive Not RecruitingNCT06068348

University of Central Florida60 enrolled

Overview

The purpose of this study is to develop a liquid biopsy approach for detection of circulating tumor cells (CTC) that could be used in place of the more invasive and potentially risky methods of tissue biopsy. The aims of the project are: (a) determine whether the Chaperonin-Containing TCP-1 (CCT) chaperonin can used to identify rare cancer cells in blood, and (b) establish whether the cancer cells detected using the CCT chaperonin for identification have invasive or metastatic potential.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chaperonin-Containing TCP-1 Circulating Tumor Cells CCT CTC

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female * Age greater than or equal to 18 and less than or equal to 80 years. Exclusion Criteria: * Adults unable to give informed consent * Individuals who are not yet adults (infants, children, teenagers; under the age of 18) * Individuals who weigh less than 110 lbs (as standard clinically advised to not give blood) * Pregnant women (due to hormonal changes in blood) * Prisoners * Persons reporting a current microbial (bacterial, viral, or fungal) infections * Persons reporting that they are current taking antibiotic medications * Persons with body temperatures above 99oF (indicating a fever)

Locations (1)

University of Central Florida

Orlando, Florida, United States

Outcomes

Primary Outcomes

To determine if the biomarker, Chaperonin-Containing TCP-1 (CCT), can be used to detect circulating tumor cells (CTC) in blood.

Time frame: 3 years

Secondary Outcomes

To determine if the CCT chaperonin can provide information on the metastatic potential of CTC.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.